Business Wire

CT-INTERACTIVE-BROKERS

8.3.2022 16:02:07 CET | Business Wire | Press release

Share
Interactive Brokers Introduces Simple Mobile App for Global Stock Trading

Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today launched IBKR GlobalTrader , a simple mobile trading application for investors to trade stocks around the world. With a streamlined design, the app is easy for novice investors to use, and powerful enough for experienced stock traders. Investors can open an account in minutes and start trading stocks on over 80 stock exchanges in North America, Europe and Asia. Investors trading with IBKR GlobalTrader benefit from Interactive Brokers’ global expertise serving over 1.75 million accounts in over 200 countries and territories.

Developed specifically for global investors, IBKR GlobalTrader conveniently lets investors make deposits in up to 23 different currencies. These deposits are automatically converted at interbank rates into the currency needed to buy and sell stocks across markets and geographies. For investors seeking global diversification but unsure of what to invest in, the IBKR GlobalAnalyst scanner helps investors identify investment opportunities worldwide. Investors can then use the IBKR GlobalTrader app to quickly take advantage of them.

“As a growing number of individuals around the world discover the benefits of actively participating in the financial markets, the need for a simple and easy to use stock trading app has never been greater,” said Steve Sanders, EVP of Marketing and Product Development at Interactive Brokers. “The IBKR GlobalAnalyst tool helps both beginners and advanced traders find investment opportunities, and then they can use the simple IBKR GlobalTrader app to trade stocks worldwide.”

Trading costs with IBKR GlobalTrader are transparent and low. For investors outside the U.S., commissions start at just USD 0.0035 per share and U.S. residents enjoy zero commissions on U.S. stocks. Commissions on Forex transactions are 3bps (0.03%) times the trade value, with no hidden spreads or markups.

Additional tools and features available on the IBKR GlobalTrader app include:

  • Fractional Shares: With fractional shares, investors can invest in U.S. shares with as little as $1, regardless of the stock price.
  • Swap: Switch positions in the same dollar amount from one security to another. With one tap, investors can buy the stocks they want and sell those they no longer want to own.
  • Crypto Trading: Trade Bitcoin (BTC), Bitcoin Cash (BCH), Ethereum (ETH) or Litecoin (LTC) via Paxos Trust Company and the IBKR GlobalTrader app. Cryptocurrency trading is available to clients of IB LLC.
  • Free Educational Resources: Investors can continually learn more about the markets, trading and investing via IBKR Campus .

IBKR GlobalTrader is available for download in the Apple App Store and on Google Play. Investors can sign up for a free trial with no commitment.

For more information, please visit:
United States and countries served by IB LLC: https://globaltrader.interactivebrokers.com
Canada: https://globaltrader.interactivebrokers.ca
United Kingdom: https://globaltrader.interactivebrokers.co.uk
Western Europe: https://globaltrader.interactivebrokers.ie
Central Europe: https://globaltrader.interactivebrokers.hu
Australia: https://globaltrader.interactivebrokers.com.au
Hong Kong: https://globaltrader.interactivebrokers.com.hk
India: https://globaltrader.interactivebrokers.co.in
Singapore: https://globaltrader.interactivebrokers.com.sg

Product eligibility and availability may vary depending on country of legal residence.

About Interactive Brokers Group, Inc.:

Interactive Brokers Group affiliates provide automated trade execution and custody of securities, commodities and foreign exchange around the clock on over 135 markets in numerous countries and currencies, from a single IBKR Integrated Investment Account to clients worldwide. We service individual investors, hedge funds, proprietary trading groups, financial advisors and introducing brokers. Our four decades of focus on technology and automation has enabled us to equip our clients with a uniquely sophisticated platform to manage their investment portfolios. We strive to provide our clients with advantageous execution prices and trading, risk and portfolio management tools, research facilities and investment products, all at low or no cost, positioning them to achieve superior returns on investments. Barron’s ranked Interactive Brokers #1 with 5 out of 5 stars in its February 26, 2021, Best Online Broker Review.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bial Announces Completion of Phase 2b ACTIVATE Study with BIA 28-6156 in GBA1-Associated Parkinson’s26.5.2026 08:00:00 CEST | Press release

Study Topline results will be released around the end of Q2 2026 BIA 28-6156 is being developed as a potential first-in-class disease-modifying therapy in GBA-PD Bial was present at the GBA1 conference and is currently attending the World Parkinson Congress Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced the completion of the treatment period in its Phase 2b ACTIVATE study of BIA 28-6156 (pariceract) in patients with Parkinson’s disease (PD) who have a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene (GBA-PD). Upon completion of the 78-week double-blind treatment period and all scheduled safety follow-ups, data cleaning and analysis are currently ongoing. Topline results will be released around the end of Q2. A status report on the ACTIVATE study was presented in an oral presentation at the 3rd International GBA1 Meeting 2026. The team is currently attending the 7th World Parkinson Congress, taking place in Pho

Oticon Medical Introduces Ponto™ Instant, Expanding Non-Surgical Choice with Instant HearBand and Instant SoundConnector26.5.2026 07:00:00 CEST | Press release

Oticon Medical today announces its new non-surgical portfolio, Ponto Instant, designed to broaden access to bone conduction hearing and offer more choice for users and hearing care professionals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525771593/en/ Left: Instant HearBand, a discreet behind-the-head wearable solution that offers an alternative to Softband 5. Right: Instant SoundConnector, a small accessory fitted to a cap or other headwear, providing another non-surgical way to wear a Ponto sound processor. The Ponto Instant portfolio includes Softband 5, Oticon Medical’s established and trusted non-surgical solution, and now expands with the launch of Instant HearBand and Instant SoundConnector, further strengthening its wearable offering for children and adults who prefer a non-surgical solution. Instant HearBand: a discreet new wearable alternative As part of the new portfolio, Instant HearBand is introduced as

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye